Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

Irinotecan Hydrochloride

  Cat. No.:  DC4180   Featured
Chemical Structure
100286-90-6
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86 21 58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Irinotecan hydrochloride is the hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.
Chemicals PropertiesBiological activity Related products COA MSDS Datasheet
Cas No.: 100286-90-6
Chemical Name: Irinotecan hydrochloride
Synonyms: Irinotecan HCL;Irinotecan, Hydrochloride, Trihydrate;Irinotecan Hydrochloride;(S)-[1,4'-Bipiperidine]-1'-carboxylic acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester hydrochloride;(S)-4,11-DIETHYL-3,4,12,14-TETRAHYDRO-4-HYDROXY-3,14-DIOXO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL ESTER;TOPOTECIN HYDROCHLORIDE;CPT 11;Irinotecan;Irinotecan (hydrochloride);Irinotecan HCL Trihydrate;IRINOTECAN HCL(P);IRINOTECAN MONOHYDROCHLORIDE TRIHYDRATE;Campto;Campto hydrochloride;Camptothecin 11 hydrochloride;Camptothecin analog;CPT 11 hydrochloride;CPT-11 hydrochloride;Topotecin;Camptosar;Camptothecin 11;U 101440E;06X131E4OE;NSC616348;Irinotecan hydrochloride [USAN:JAN];DSSTox_RID_81249;DSSTox_CID_25953;DSSTox_GSID_45953;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hy...
SMILES: Cl.CCC1C2=C(N=C3C=1C=C(C=C3)OC(=O)N4CCC(CC4)N5CCCCC5)C6N(C2)C(=O)C7=C(C=6)[C@](CC)(O)C(=O)OC7
Formula: C33H39ClN4O6
M.Wt: 623.1390
Purity: 99%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Irinotecan hydrochloride is a water soluble topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer.
Target: Topoisomerase I
In Vivo: Irinotecan (CPT-11, 5 mg/kg) significantly inhibits the growth of tumors by intratumoral injection daily for 5 days, on two consecutive weeks in rats, and such effects also occur via continuous intraperitoneal infusion by osmotic minipump into mice. However, Irinotecan (10 mg/kg) shows no effect on the growth of tumor by i.p[1]. Irinotecan (CPT-11, 100-300 mg/kg, i.p.) apparently suppresses tumor growth of HT-29 xenografts in athymic female mice by day 21. The two groups of Irinotecan (125 mg/kg) plus TSP-1 (10 mg/kg per day) or Irinotecan (150 mg/kg) in combination TSP-1 (20 mg/kg per day) are nearly equally effective and inhibit tumor growth 84% and 89%, respectively, and both are more effective than Irinotecan alone at doses of 250 and 300 mg/kg[3].
In Vitro: Irinotecan hydrochloride is a topoisomerase I inhibitor. Irinotecan inhibits the growth of LoVo and HT-29 cells, with IC50s of 15.8 ± 5.1 and 5.17 ± 1.4 μM, respectively, and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells[2]. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC), with an IC50 of 1.3 μM[3].
Cell Assay: Exponentially growing cells are seeded in 20 cm2 dishes with an optimal cell number for each cell line (20,000 for LoVo cells, 100,000 for HT-29 cells). They are treated 2 days later with increasing concentrations of irinotecan or SN-38 for one cell doubling time (24 h for LoVo cells, 40 h for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the drug concentrations responsible for 50% growth inhibition as compared with cells incubated without drug[2].
Animal Administration: Irinotecan has been administered by intratumoral injection at 0.1 cc volume of the appropriate solution, for a doses of 5 mg/kg daily for 5 days, on two consecutive weeks, followed by a 7-days rest period, referred to as one cycle of therapy. Rats receive three cycles over a period of 8 weeks. Control animals receive 0.1 cc of sterile 0.9% sodium chloride solution by intratumoral injection in the same rule of administration as that of animals of group II[1].
References: [1]. Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56(3):219-26. [2]. Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49(4):329-35. Epub 2002 Jan 30. [3]. Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5.
Cat. No. Product name Field of application
DC31074 Isopropyl myristate Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC79609 NCGC00685960 NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 < 10  nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research.
DC77831 Vicadrostat Vicadrostat (compound 29 A) is a potent and selective inhibitor of aldosterone synthase(CYP11B2) with an IC50 of 16 nM. It exhibits potential in renal disease, diabetic nephropathy, cardiovascular diseases and fibrotic disorder research.
DC77813 Zeltociclib Zeltociclib is a cyclin-dependent kinase inhibitor with antitumor effects.
DC77714 S3226 S3226 is an inhibitor for Na+/H+ exchange subtype 3 (NHE3) with an IC50 of 0.2 µmol/L in rat NHE3 transfected fibroblasts. S3226 exhibits protective activity in rat ischemia-induced acute renal failure models.
DC77387 AUR1545 AUR1545 is a selective degrader of KAT2A and KAT2B. AUR1545 can be used in the cancer research, including studies on AML (Acute myeloid leukemia), SCLC (Small-cell carcinoma), and NEPC (Neuroendocrine Prostate Cancer).
DC77822 JNJ-77242113 (Icotrokinr) Icotrokinra (JNJ-77242113, JNJ-2113, PN-235) is an orally available and selective antagonist of the IL-23 receptor. It also inhibits IL-23–induced STAT3 phosphorylation in peripheral blood mononuclear cells with an IC50 of 5.6 pM and suppresses IL-23–induced IFN-γ production in NK cells with an IC50 of 18.4 pM. It also exhibits anti-inflammatory activity in a TNBS-induced colitis model in rats and holds potential for studying psoriasis, psoriatic arthritis, and inflammatory bowel disease.
DC77088 T025 T025 is as an orally available and potent inhibitor of Cdc2‐like kinases (CLKs) with an IC50s of 0.93 nM, 1 nM, 14 nM, 1.5 nM for CLK1, CLK2, CLK3, DYRK1B respectively. It exhibits anti‐tumor efficacy and can be used in MYC‐driven cancer research.
DC75868 AZ14133346 AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865 TI17 ​​TI17​​ represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia